AAA
BDTX icon

Affinity Asset Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Affinity Asset Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-250,000
Closed -$388K – 94
2025
Q1 		$388K Sell
250,000
-309,163
-55% -$648K 0.04% 87
2024
Q4 		$1.2M Buy
+559,163
New +$1.6M 0.16% 68
2024
Q3 		– Sell
-650,000
Closed -$3.03M – 89
2024
Q2 		$3.03M Buy
+650,000
New +$3.49M 0.35% 55

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Affinity Asset Advisors's BDTX Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 250,000 shares — an estimated $388K sold.

Affinity Asset Advisors first reported a position in BDTX in Q2 2024 and held it in 3 quarters. The position peaked at $3.03M in Q2 2024. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Black Diamond Therapeutics shares in Q2 2025, an estimated $388K.
  • Affinity Asset Advisors first reported a position in Black Diamond Therapeutics in Q2 2024 and held it in 3 quarters.
  • Affinity Asset Advisors's Black Diamond Therapeutics position peaked at $3.03M in Q2 2024.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.